Blog
RSS FeedPosted by Michael Wonder on 23 Oct 2017
Taxpayer-funded drugs 'too expensive for patients’
22 October 2017 - Taxpayer-funded medical research is producing medicines which are increasingly unaffordable for patients who need them, says ...
Posted by Michael Wonder on 20 Oct 2017
National PreP service would be cost effective, research finds
20 October 2017 - Providing pre-exposure prophylaxis treatment to men who have sex with men at high risk of contracting ...
Posted by Michael Wonder on 20 Oct 2017
NICE no for Opdivo in urothelial carcinoma
20 October 2017 - The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for ...
Posted by Michael Wonder on 18 Oct 2017
Economic evaluation of personalised medicine: a call for real-world data
18 October 2017 - In the last decade, we have witnessed a change in healthcare management, with ‘personalised medicine’ as the ...
Posted by Michael Wonder on 17 Oct 2017
‘No-deal’ Brexit could cost NHS £500m a year
17 October 2017 - A ‘no-deal’ Brexit that ends healthcare arrangements between the UK and the EU could end up ...
Posted by Michael Wonder on 16 Oct 2017
Roche’s skin cancer drug Erivedge pulled from CDF
13 October 2017 - Roche’s Erivedge could be removed from the Cancer Drugs Fund within months after the National Institute ...
Posted by Michael Wonder on 16 Oct 2017
Social value and individual choice: the value of a choice-based decision-making process in a collectively funded health system
4 October 2017 - Evidence about cost-effectiveness is increasingly being used to inform decisions about the funding of new technologies that ...
Posted by Michael Wonder on 13 Oct 2017
Hundreds of patients to have access to head and neck cancer drug after new deal, says NICE
13 October 2017 - Nivolumab is recommended for use within the Cancer Drugs Fund for some patients with head and neck ...
Posted by Michael Wonder on 12 Oct 2017
New treatment option for people with gastro-intestinal cancer
12 October 2017 - More people will be able to receive regorafenib now that NICE has said it should move out ...
Posted by Michael Wonder on 11 Oct 2017
Xeljanz receives positive reimbursement decision in England
11 October 2017 - The UK’s HTA body NICE has provided final guidance recommending Xeljanz (tofacitinib citrate) as a treatment ...
Posted by Michael Wonder on 09 Oct 2017
Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
9 October 2017 - Healthcare systems depend on the availability of new antibiotics. ...
Posted by Michael Wonder on 07 Oct 2017
Leukaemia patients to get access to AbbVie’s Venclyxto via Cancer Drugs Fund
5 October 2017 - AbbVie has struck a deal with NICE to make its leukaemia drug Venclyxto available through the ...
Posted by Michael Wonder on 05 Oct 2017
ABPI update on application for judicial review
4 October 2017 - The ABPI have issued a statement regarding its application for judicial review versus NICE. ...
Posted by Michael Wonder on 30 Sep 2017
Improved access? The reality of the PPRS
29 September 2017 - In the third in her series of five articles, Leela Barham considers the extent to which ...
Posted by Michael Wonder on 29 Sep 2017
Price deal sees NICE back Imbruvica for one indication but not another
28 September 2017 - The UK’s NICE has recommended Imbruvica (ibrutinib), within its marketing authorisation, for use on the Cancer ...